Vaccine platforms to control arenaviral hemorrhagic fevers

Journal of Vaccines and Vaccination

Volumn 3, Issue 7, 2012, Pages

  Carrion Jr , Ricardo ^a   Bredenbeek, Peter ^b   Jiang, Xiaohong ^b   Tretyakova, Irina ^c   Pushko, Peter ^c   Lukashevich, Igor S ^d  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Medigen Inc   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Arenaviruses; Junin; Lassa; Macupo; Vaccines; VEEV TC 83 based replicons; YF17D Lassa; YF17D vector

Indexed keywords

EID: 84871563432     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000160     Document Type: Article

References (64)

1. Salvato MS, Clegg JCS, Buchmeier MJ, Charrel RN, Gonzalez JP, et al. (2012) Family arenaviridae, virus taxonomy, classification and nomenclature of viruses, Ninth Report of the International Committee on Taxonomy of Viruses. Academic Press, Elsevier Inc., 715-723.
2. Bonthius DJ (2012) Lymphocytic choriomeningitis virus: an underrecognized cause of neurologic disease in the fetus, child, and adult. Semin Pediatr Neurol 19: 89-95.
3. MacNeil A, Ströher U, Farnon E, Campbell S, Cannon D, et al. (2012) Solid organ transplant-associated lymphocytic choriomeningitis, United States, 2011. Emerg Infect Dis 18: 1256-1262.
4. Erickson BR, Delgado S, Aguda R, et al. (2006) A newly discovered arenavirus associated with a fatal hemorrhagic fever case in Bolivia. XIII Intern. Confer. on Negative Strand Viruses, Abstracts, 212.
5. Paweska J, Sewlall NH, Ksiazek TG, Blumberg LH, Hale MJ, et al. (2009) Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 15: 1598-1602.
6. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, et al. (2009) Genetic detection and characterization of lujo virus, a new hemorrhagic feverassociated arenavirus from southern africa. PLoS Pathog 5: e1000455.
7. Lecompte E, Meulen JT, Emonet S, Daffis S, Charrel RN (2007) Genetic identification of Kodoko virus, a novel arenavirus of the African pigmy mouse (Mus Nannomys minutoides) in West Africa. Virology 364: 178-183.
8. Ishii A, Thomas Y, Moonga L, Nakamura I, Ohnuma A, et al. (2011) Novel arenavirus, Zambia. Emerg Infect Dis 17: 1921-1924.
9. Palacios G, Savji N, Hui J, Travassos da Rossa, Popov V, et al. (2010) Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J Gen Virol 91: 1315-1324.
10. Coulibaly-N'Golo D, Allali B, Kouassi SK, Fichet-Calvet E, Becker-Ziaja B et al. (2011) Novel Arenavirus Sequences in Hylomyscus sp. and Mus (Nannomys) setulosus from Cote d'Ivoire: Implications for Evolution of Arenaviruses in Africa. PLoS One 6: e20893.
11. Stenglein MD, Sanders C, Kistler AL, Ruby JG, Franco JY, et al. (2012) Identification, characterization, and in vitro culture of highly divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiological agents for snake inclusion body disease. MBio 3: e00180-12.
12. Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, et al. (2005) A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 79: 13934-13942.
13. Lukashevich IS, Carrion R Jr, Salvato MS, Mansfield K, Brasky K, et al. (2008) Safety, immunogenicity, and efficacy of the ML29 vaccine for Lassa fever in small non-human primates. Vaccine 26: 5246-5254.
14. Carrion R Jr, Patterson JL, Johnson C, Gonzales M, Moreira CR, et al. (2007) A ML29 reassortant virus protects guinea pigs against a distantly-related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25: 4093-4102.
15. Bredenbeek P, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, et al. (2006) A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345: 299-304.
16. Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, et al. (2011) Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29: 1248-1257.
17. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75: 11677-11685.
18. Lukashevich IS (1992) Generation of reassortants between African arenaviruses. Virology 188: 600-605.
19. Moshkoff D, Salvato MS, Lukashevich IS (2006) Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes 34: 169-176.
20. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT Jr, et al. (1987) Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 134: 5-68.
21. Boudko SP, Londer YY, Letarov AV, Sernova NV, Engel J, et al. (2002) Domain organization, folding and stability of bacteriophage T4 fibritin, a segmented coiled-coil protein. Eur J Biochem 269: 833-841.
22. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, et al. (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239: 389-401.
23. Fisher-Hoch SP, McCormick JB (2004) Lassa fever vaccine. Expert Rev Vaccines 3: 103-111.
24. Meulen J, Badusche M, Satoguina J, Strecker T, Lenz O, et al. (2004) Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321: 134-143.
25. Ter Meulen J, Badusche M, Kuhnt K, Doetze A, Satoguina J, et al. (2000) Characterization of human CD4+ T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol 74: 2186-2192.
26. Lukashevich IS (2010) A live reassortant vaccine for Lassa Fever. In: EM Vela (Ed): Molecular Pathogenesis of Hemorrhagic Fever Viruses, Transw Res Net, Kerala, India. 143-170.
27. Salvato MS, Lukashevich IS (2009) Vaccines against Lassa fever: New Generation Vaccines, (4thedn), Marcel Dekker Inc, 895-904.
28. Fisher-Hoch SP, McCormick JB (2004) Lassa fever vaccine. Expert Rev Vaccines 3: 189-197.
29. Monath TP (2005) Yellow fever vaccine. Expert Review of Vaccines 4: 553-574.
30. Lukashevich IS, Salvato MS (2006) Lassa Virus Genome. Current Genomics 7: 351-379.
31. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314: 20-26.
32. Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, et al. (2011) Human Dendritic Cells Infected with the Nonpathogenic Mopeia Virus Induce Stronger T-Cell Responses than Those Infected with Lassa Virus. J Virol 85: 8293-8306.
33. Daddario-DiCaprio KM, Geisbert TW, Ströher U, Geisbert JB, Grolla A, et al. (2006) Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367: 1399-1404.
34. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, et al. (2008) Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates. J Virol 82: 5664-5668.
35. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, et al. (2007) Effective Post-Exposure Treatment of Ebola Infection. PLoS Pathog 3: e2.
36. Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, et al. (2011) Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204: S785-S790.
37. Fisher-Hoch S, McCormick J (2001) Towards a human Lassa fever vaccine. Rev Med Virol 11: 331-341.
38. Editorial. YF17D vector for Lassa fever vaccine. International Innovation, 77-79.
39. Hayes EB (2007) Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 101: 967-971.
40. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, et al. (2008) Adverse event reports following yellow fever vaccination. Vaccine 26: 6077-6082.
41. Silva ML, Espírito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhães V, et al. (2010) Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol 17: 118-126.
42. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, et al. (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632-649.
43. Appaiahgari MB, Vrati S (2012) Clinical development of IMOJEV®-a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther 12: 1251-1263.
44. Schildknecht A, Welti S, Geuking MB, Hangartner L, Van den Broek M (2008) Absence of CTL Responses to Early Viral Antigens Facilitates Viral Persistence. J Immunol 180: 3113-3121.
45. Russier M, Pannetier D, Baize S (2012) Immune Responses and Lassa Virus Infection. Viruses 4: doi:10.3390/v3340x3000x, in press.
46. Shedlock DJ, Talbott KT, Cress C, Ferraro B, Tuyishme S, et al. (2011) A highly optimized DNA vaccine confers complete protective immunity against highdose lethal lymphocytic choriomeningitis virus challenge. Vaccine 29: 6755-6762.
47. Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, et al. (2009) Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys. J Virol 83: 5890-5903.
48. Carnec X, Baize S, Reynard S, Diancourt L, Caro V, et al. (2011) Lassa virus nucleoprotein mutants generated by reverse genetics induce robust type I IFN response in human dendritic cells and macrophages. J Virol 85: 12093-12097.
49. Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF, et al. (2004) CD8+ T cell cross-priming via transfer of proteasome substrates. Science 304: 1318-1321.
50. Huckriede A, Bungener L, Holtrop M, de Vries J, Waarts BL, et al. (2004) Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine 22: 1104-1113.
51. Vander Veen R, Harris DL, Kamrud KI (2012) Alphavirus replicon vaccines. Anim Health Res Rev 13: 1-9.
52. Thompson JM, Whitmore AC, Staats HF, Johnston RE (2008) Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to codelivered antigen. Vaccine 26: 4267-4275.
53. Balasuriya U, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, et al. (2002) Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20: 1609-1617.
54. Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, et al. (2000) Genetic diversity among Lassa virus strains. J Virol 74: 6992-7004.
55. Schliehe C, Bitzer A, van den Broek M, Groettrup M (2012) Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol 86: 9782-9793.
56. Freigang S, Eschli B, Harris N, Geuking M, Quirin K, et al. (2007) A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8(+) T cell responses. Proc Natl Acad Sci U S A, 104: 13426-13431.
57. Goicocheaa MA, Zapata JC, Bryant J, Davis H, Salvato MS, et al. (2012) Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine 30: 1445-1452.
58. Enria DA, Barbera Oro JG (2002) Junin Virus Vaccines. Curr Top Microbiol Immunol 263: 239-261.
59. McKee KTJ, Oro JG, AL Kuehne JA Spisso, Mahlandt BG (1993) Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. Am J Trop Med Hyg 48: 403-411.
60. Aguilar PV, Camargo W, Vargas J, Guevara C, Roca Y, et al. (2009) Reemergence of Bolivian Hemorrhagic Fever, 2007-2008. Emerg Infect Dis 15: 1526-1528.
61. Radoshitzky SR, Kuhn JH, de Kok-Mercado F, Jahrling PB, Bavari S (2012) Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin Drug Discov 7: 613-632.
62. Seregin AV, Yun NE, Poussard AL, Peng BH, Smith JK, et al. (2010) TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine 28: 4713-4718.
63. Sanchez A, Pifat DY, Kenyon RH, Peters CJ, McCormick JB, et al. (1989) Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J Gen Virol 70: 1125-1132.
64. Demby AH, Chamberlain J, Brown DW, Clegg CS (1994) Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol 32: 2898-2903.